Skip to main content
. 2011 Sep 7;90(4):625–629. doi: 10.1038/clpt.2011.185

Table 1.

Recommended daily warfarin doses (mg/day) to achieve a therapeutic INR based on CYP2C9 and VKORC1 genotype using the warfarin product insert approved by the US Food and Drug Administration

VKORC1:–1639G>A CYP2C9*1/*1 CYP2C9*1/*2 CYP2C9*1/*3 CYP2C9*2/*2 CYP2C9*2/*3 CYP2C9*3/*3
GG 5–7 5–7 3–4 3–4 3–4 0.5–2
GA 5–7 3–4 3–4 3–4 0.5–2 0.5–2
AA 3–4 3–4 0.5–2 0.5–2 0.5–2 0.5–2

Reproduced from updated warfarin (Coumadin) product label.